Terapia Intensiva
Editorial | Uso excessivo de antibióticos: gerenciamento da incerteza e mitigação contra o tratamento em excesso.
26 Jul, 2021 | 09:58hAntibiotic overuse: managing uncertainty and mitigating against overtreatment – BMJ Quality & Safety
Comentário no Twitter
Our editorial in @BMJ_Qual_Saf discusses uncertainty and antibiotic overuse, and identifies 4 strategies to address the tendency to prescribe 'just in case'. @EM_Krockow https://t.co/kvIG5uxxOL pic.twitter.com/eTIuqGOj1o
— Prof Carolyn Tarrant (@carolynctarrant) July 21, 2021
Opinião | Tocilizumabe no tratamento da COVID-19: quem se beneficia e como? – Os pesquisadores sugerem que inibidores de IL-6 talvez devam ser ministrados somente a pacientes com altos níveis de IL-6.
23 Jul, 2021 | 10:18hTocilizumab in COVID-19 therapy: who benefits, and how? – The Lancet
Relacionado: A living WHO guideline on drugs for covid-19 – interleukin-6 receptor blockers are now recommended for patients with severe or critical covid-19. E M-A: Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 – “The 4% absolute risk reduction in mortality from 25% to 21% with IL-6 inhibition added to glucocorticoids may not translate to patients with a lower baseline mortality risk and likely do not justify the additional expense and risk for toxicities for patients hospitalized with modest oxygen requirements and a stable clinical course (from editorial)”. E RECOVERY trial: In hospitalized COVID-19 patients with hypoxia and systemic inflammation (C-reactive protein ≥75 mg/L), tocilizumab improved survival and other clinical outcomes E Secondary analysis of RCT finds Tocilizumab was beneficial to patients hospitalized with Covid-19 if CRP levels were greater than 15.0 mg/dL, but not if CRP levels were 15.0 mg/dL or less. E M-A: Tocilizumab in COVID-19 – “For hospitalized COVID-19 patients, there is some evidence that tocilizumab use may be associated with a short-term mortality benefit, but further high-quality data are required”.
Colangite esclerosante secundária: uma nova complicação em pacientes críticos com COVID-19.
23 Jul, 2021 | 10:16hRevisão | Estratégias de tratamento para fibrilação atrial que se inicia na unidade de terapia intensiva.
23 Jul, 2021 | 10:06hRevisão | Ética no uso do suporte respiratório extracorpóreo.
23 Jul, 2021 | 10:05hEthics in extracorporeal life support: a narrative review – Critical Care
Revisão sobre as diferentes vias de administração de medicamentos para dor pós-operatória aguda.
22 Jul, 2021 | 12:58hThe Routes of Administration for Acute Postoperative Pain Medication – Pain and Therapy
Revisão | Ventilação mecânica personalizada na sindrome da angustia respiratoria aguda.
22 Jul, 2021 | 12:52hPersonalized mechanical ventilation in acute respiratory distress syndrome – Critical Care
Relacionado: M-A of randomized trials: In patients with acute respiratory distress syndrome, there was no difference in mortality between higher vs. lower positive end-expiratory pressure strategies. E Seminar | Acute respiratory distress syndrome. E Short review: Diagnosis and management of acute respiratory distress syndrome
Uma revisão narrativa sobre o papel da bacteriúria por Staphylococcus aureus na bacteriemia por S. aureus.
22 Jul, 2021 | 12:52h
Comentário no Twitter
✨If you have Staph in urine check blood culture✨
💥Excellent narrative review on the role of Staphylococcus aureus Bacteriuria in S. aureus Bacteremia
Epidemiology and pathogenesis of SABU in patients with SAB💥 #IDTwitter #ofid https://t.co/wioI3I528z pic.twitter.com/54jVQEBeDW— Antibiotic Steward 🆔🇵🇸 Bassam Ghanem (@ABsteward) March 30, 2021
Estudo randomizado | Realimentação oral imediata em pacientes com pancreatite aguda leve e moderada.
22 Jul, 2021 | 12:50hImmediate Oral Refeeding in Patients With Mild and Moderate Acute Pancreatitis: A Multicenter, Randomized Controlled Trial (PADI trial) – Annals of Surgery (link para o resumo – $ para o texto completo)
Estudo de coorte | Anemia falciforme e desfechos de COVID-19 – “Nossa análise estima um aumento de 4 vezes no risco de hospitalização por COVID-19 e de 2,6 vezes no risco de morte relacionada a COVID-19 em pacientes com anemia falciforme.”
21 Jul, 2021 | 09:55hSickle Cell Disorders and Severe COVID-19 Outcomes: A Cohort Study – Annals of Internal Medicine